Goal 3: Advance Translational Research

To facilitate innovation and accelerate research translation, knowledge dissemination, and implementation science that enhances public health.

Goal 3: Advance Translational Research

Leveraging PEPFAR infrastructure for CVDs

How do we go about leveraging existing infrastructure, such as PEPFAR, to reduce the risk of HLBS diseases among HIV patients and other vulnerable populations? • Common goals and deliverables between NHLBI and partners will need to be identified • The best return on investment of NHLBI funds will need to be determined • Feasible T4 translation interventions in PEPFAR funded studies utilizing HIV populations with HLBS ...more »

Submitted by (@nhlbiforumadministrator)

Voting

-1 net votes
7 up votes
8 down votes
Active

Goal 3: Advance Translational Research

Microvascular Dementia

The catchword Alzheimer's Disease (AD) is used to describe almost all types of dementia these days, and a lot of work has gone into developing preventive and/or therapeutic interventions for AD, but studies show that 40% of "AD" patients may in fact have something else. Microvascular Dementia (MD) presents with a similar phenotype. Delineating these two entities and then developing treatment strategies for MD is my ...more »

Submitted by (@wmars0)

Voting

8 net votes
16 up votes
8 down votes
Active

Goal 3: Advance Translational Research

Developing Curative Approaches to Cardiovascular Disease rather than Chronic Magement

Most Pharmacological interventions in cardiovascular diseases tend to address to be used in palliative manner and chronically. There is urgent need for treatments that are curative. This goes to identifying molecular drivers of the diseases and targeting them to correct the underlying pathophysiology rather than symptom suppression.

Submitted by (@john.buolamwini)

Voting

1 net vote
2 up votes
1 down votes
Active

Goal 3: Advance Translational Research

Regenerative Medicine 2.0 in Heart and Lung Research - Back to the Drawing Board

Stem cell therapies have been quite successful in hematologic disease but the outcomes of clinical studies using stem cells for cardiopulmonary disease have been rather modest. Explanations for this discrepancy such as the fact that our blood has a high rate of physiologic, endogenous turnover and regeneration whereas these processes occur at far lower rates in the heart and lung. Furthermore, hematopoietic stem cells ...more »

Submitted by (@jalees)

Voting

7 net votes
11 up votes
4 down votes
Active

Goal 3: Advance Translational Research

Don’t ask, don’t tell; the hidden costs of heart, lung & stem cell transplantation:Financial burden on transplant survivors

Thousands of patients get cured of their diseases with organ and/or hematopoietic stem cell transplantation (HSCT), but what happens after that to their social and financial life? Drug costs, multiple tests, travel to transplant centers, and many other factors cost a fortune to the patients (and their insurers). Can the NHLBI provide systems based approach longitudinally to alleviate the long term cost burden on patients ...more »

Submitted by (@hashmi.shahrukh)

Voting

25 net votes
42 up votes
17 down votes
Active